Literature DB >> 12672258

14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.

Peter Grundt1, Andrew R Jales, John R Traynor, John W Lewis, Stephen M Husbands.   

Abstract

The 14-amino analogue of oxymorphindole (OMI) was synthesized and found to possess delta-opioid binding affinity and selectivity similar to OMI. Substitution of the amino group with alkyl, arylalkyl, and acyl groups had relatively little effect on delta-affinity but delta-selectivity was reduced. In functional assays the 14-phenylacetylamino derivative 6d was a selective delta-agonist whereas the phenethylamino analogue 5d was a mu-agonist and low efficacy delta partial agonist that warrants further investigation as an analgesic with low tolerance and dependence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672258     DOI: 10.1021/jm021073r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

Review 1.  Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.

Authors:  Subramaniam Ananthan
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

2.  3D-QSAR studies of orvinol analogs as kappa-opioid agonists.

Authors:  Wei Li; Yun Tang; Qiong Xie; Wei Sheng; Zhui-Bai Qiu
Journal:  J Mol Model       Date:  2006-03-22       Impact factor: 1.810

3.  14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Authors:  Guo Li; Lindsey C K Aschenbach; Hengjun He; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-12-29       Impact factor: 2.823

4.  Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.

Authors:  Gerta Cami-Kobeci; Adrian P Neal; Faye A Bradbury; Lauren C Purington; Mario D Aceto; Louis S Harris; John W Lewis; John R Traynor; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.